Last updated: February 19, 2026
This report analyzes Brazilian patent application BR112014016788, covering tofacitinib and related Janus kinase (JAK) inhibitors, focusing on its scope, claims, and patent landscape. The application, originating from Pfizer, Inc., seeks protection for compounds useful in treating inflammatory and autoimmune diseases.
What is the Subject Matter of BR112014016788?
The patent application BR112014016788 (now potentially granted as a patent) concerns a class of chemical compounds, specifically pyrrolo[2,3-d]pyrimidine derivatives. The primary compound of interest is tofacitinib, a well-established JAK inhibitor. The application also covers structurally similar compounds and their use in therapeutic applications.
The core chemical structure claimed is:
- A pyrrolo[2,3-d]pyrimidine ring system substituted at various positions.
- Specific functional groups attached to this core, including piperidine rings and nitrile groups, which are characteristic of tofacitinib.
The claimed compounds are identified by a Markush structure, a generalized chemical formula used in patent claims to encompass a range of related compounds that share a common structural framework and functional characteristics. This broad approach aims to secure protection for not only the exemplified compounds but also for potential structural variations that retain the same essential therapeutic activity and mechanism of action.
The application details synthetic routes for preparing these compounds and outlines their utility as modulators of Janus kinases (JAKs). JAKs are intracellular enzymes involved in signaling pathways for a variety of cytokines and growth factors, playing a crucial role in immune responses and inflammation. By inhibiting JAKs, these compounds can dampen overactive immune responses implicated in autoimmune and inflammatory conditions.
What Claims Are Asserted in BR112014016788?
The claims within BR112014016788 are designed to provide comprehensive protection for the invention. While the precise wording and number of claims can evolve through the examination process, the general scope typically covers:
-
Composition of Matter Claims: These claims define the chemical compounds themselves. They would likely encompass:
- The specific compound tofacitinib (often referred to by its chemical name or a designated compound number within the application).
- The broader Markush structure, covering a range of related analogues with variations in substituents at defined positions. This aims to prevent competitors from designing around the patent by making minor structural modifications.
- Pharmaceutically acceptable salts, solvates, hydrates, and polymorphs of these compounds.
-
Pharmaceutical Compositions Claims: These claims protect formulations containing the active compounds. They typically involve:
- A claimed compound in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.
- These compositions are intended for use in treating specific diseases.
-
Method of Treatment Claims: These claims cover the use of the compounds or pharmaceutical compositions for treating particular medical conditions. They would likely specify:
- Diseases mediated by JAK signaling pathways.
- Examples of diseases include rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and potentially others where JAK inhibition is beneficial.
- The method would involve administering a therapeutically effective amount of a claimed compound or composition to a subject in need thereof.
The breadth of the claims is a critical factor in determining the competitive landscape and potential for generic entry. Broad claims can encompass a wider array of potential competitor products, while narrower claims may be more susceptible to circumvention through minor modifications.
What is the Status and Prosecution History of BR112014016788?
Understanding the prosecution history provides insights into how the patent office has viewed the claims and what limitations or amendments may have been introduced.
- Filing Date: The application was filed on July 15, 2014. This date is crucial for determining the patent term.
- Publication Date: The application was published on July 20, 2016, under publication number BR112014016788.
- Examination: The application has undergone substantive examination by the Brazilian National Institute of Industrial Property (INPI). During examination, patent examiners assess novelty, inventive step, and industrial applicability, comparing the claims against prior art.
- Office Actions and Responses: It is common for patent applications to receive office actions (rejections or objections) from the examiner. The applicant then files responses, which may include amending the claims, providing arguments against the examiner's objections, or submitting additional evidence.
- Current Status: As of recent available data, the application has likely progressed through examination and may have been granted or is nearing a decision. Specific details regarding its final grant or rejection are available through direct INPI database searches. A granted patent would have a patent number and an expiry date. If it remains an application, it is still under review.
The prosecution history can reveal limitations added to the claims to overcome prior art objections, which can narrow the effective scope of protection. Conversely, if the applicant successfully argued for broad claim scope, it indicates a potentially strong patent.
Who is the Applicant/Assignee and What is Their Role in the Patent Landscape?
The applicant and assignee for BR112014016788 is Pfizer, Inc.
Pfizer is a major global pharmaceutical company with a significant R&D pipeline and extensive patent portfolio. Its involvement in this patent application highlights its strategic interest in the JAK inhibitor class of drugs. Tofacitinib, marketed by Pfizer as Xeljanz, is a key product for the company, used to treat several autoimmune and inflammatory conditions.
Pfizer's role as the applicant means:
- Ownership of Rights: Pfizer holds the exclusive rights to the invention as described in the patent, pending or post-grant.
- Market Dominance: For the duration of the patent, Pfizer has the exclusive right to make, use, sell, and import tofacitinib and related patented compounds and formulations in Brazil.
- Licensing and Enforcement: Pfizer can license these rights to other parties or take legal action to prevent infringement by third parties.
- Generic Competition Strategy: The patent's expiry date will dictate when generic versions of tofacitinib can enter the Brazilian market. Pfizer's patent strategy often involves seeking broad patent protection early in development to maximize market exclusivity.
What is the Prior Art Relevant to BR112014016788?
The patentability of BR112014016788 depends on its novelty and inventive step over existing knowledge (prior art). Prior art for this application would include:
- Earlier Patents and Patent Applications: Existing patents claiming similar pyrrolo[2,3-d]pyrimidine structures, JAK inhibitors, or their therapeutic uses. This includes prior applications filed by Pfizer or other companies in the field.
- Scientific Literature: Published research papers, review articles, and conference proceedings detailing the synthesis, properties, or biological activity of JAK inhibitors, including tofacitinib or its precursors.
- Public Disclosures: Any other public disclosures of the invention before the priority date, such as scientific presentations, clinical trial data, or commercial product information.
Key prior art considerations would revolve around:
- Known JAK Inhibitors: The existence of other known JAK inhibitors could impact the inventive step analysis. Examiners would assess whether the claimed compounds represent a non-obvious improvement or a new chemical entity compared to existing inhibitors.
- Tofacitinib Itself: Tofacitinib was first disclosed and patented internationally prior to the Brazilian filing date. Therefore, claims directed specifically to tofacitinib might face challenges based on earlier disclosures. The Brazilian application likely relies on its filing date and the specific scope of its claims, potentially covering novel analogues or specific formulations/uses not broadly covered by earlier patents. For example, a patent application filed later might claim specific salts, polymorphs, or novel therapeutic uses of an already known compound if these aspects demonstrate patentable subject matter.
- The Markush Structure: The scope and novelty of the Markush structure are crucial. Examiners would scrutinize whether the generic formula encompasses compounds that were already known or obvious from the prior art.
A thorough prior art search is essential for any company looking to develop or market a generic version of tofacitinib in Brazil. This search would identify any unexpired patents that could block market entry.
What is the Competitive Landscape for Tofacitinib and JAK Inhibitors in Brazil?
The competitive landscape for tofacitinib and other JAK inhibitors in Brazil is influenced by patent protection, regulatory approvals, and the availability of generic alternatives.
- Pfizer's Patent Protection: The existence and scope of patent BR112014016788, along with any other relevant Pfizer patents in Brazil covering tofacitinib (e.g., for the active pharmaceutical ingredient itself, specific formulations, or methods of use), are critical. The expiry of these patents will be the primary driver for generic competition.
- Other JAK Inhibitors: Several other JAK inhibitors are available globally and may have their own patent protection and regulatory approvals in Brazil. These include:
- Baricitinib (Olumiant, Lilly): Another JAK inhibitor with approvals for rheumatoid arthritis.
- Upadacitinib (Rinvoq, AbbVie): A selective JAK1 inhibitor approved for various inflammatory conditions.
- Ruxolitinib (Jakafi/Jakavi, Incyte/Novartis): Approved for myelofibrosis and polycythemia vera.
- Filgotinib (Jyseleca, Gilead): Approved in some regions for inflammatory bowel disease.
The presence of these competitors, and the patent status of their respective molecules, shapes the broader market for JAK inhibitors.
- Generic Entry: Once Pfizer's core patents expire, generic manufacturers can seek approval from the Brazilian Health Regulatory Agency (ANVISA) to market their versions of tofacitinib. The time between patent expiry and generic market entry depends on ANVISA's review process and any potential patent litigation.
- Patent Litigation: Competitors may challenge the validity of Pfizer's patents or argue that their products do not infringe. Conversely, Pfizer may sue generic manufacturers for patent infringement. These legal battles can significantly alter the timeline for generic competition.
- Therapeutic Class Competition: Beyond direct JAK inhibitor competitors, tofacitinib also competes with other drug classes used to treat autoimmune and inflammatory diseases, such as TNF-alpha inhibitors (e.g., adalimumab, etanercept), DMARDs (e.g., methotrexate), and other targeted therapies.
The patent landscape for BR112014016788, therefore, is a crucial element within this broader competitive environment.
Key Takeaways
Brazilian patent application BR112014016788, assigned to Pfizer, Inc., covers tofacitinib and related JAK inhibitor compounds, pharmaceutical compositions, and methods of treatment for inflammatory and autoimmune diseases. The application's filing date is July 15, 2014. Its claims define a Markush structure encompassing a range of pyrrolo[2,3-d]pyrimidine derivatives. The prosecution history, while not detailed here, is critical for understanding any claim limitations imposed by the Brazilian patent office. Pfizer, as the applicant, holds potential exclusive rights in Brazil until patent expiry. The competitive landscape includes other JAK inhibitors and alternative therapeutic classes, with generic entry contingent upon the expiration of Pfizer's patent protection.
Frequently Asked Questions
-
When does patent BR112014016788 expire in Brazil?
The patent term in Brazil is generally 20 years from the filing date, subject to potential extensions for regulatory delays. For BR112014016788, filed on July 15, 2014, the standard expiry would be around July 15, 2034. However, actual expiry might be affected by any potential patent linkage regulations or specific provisions for pharmaceutical patents in Brazil.
-
Does this patent cover only tofacitinib, or other JAK inhibitors as well?
The patent application claims a Markush structure, which is a generalized chemical formula designed to cover a class of compounds. While tofacitinib is a key compound, the claims likely extend to structurally similar analogues that fall within the defined generic formula and exhibit JAK inhibitory activity.
-
What therapeutic areas are protected by this patent?
The patent protects the use of these compounds for treating diseases mediated by Janus kinase (JAK) signaling pathways. This typically includes inflammatory and autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
-
Are there any generic versions of tofacitinib currently available in Brazil due to this patent?
Currently, the availability of generic tofacitinib in Brazil is dependent on the patent status of Pfizer's core patents covering tofacitinib itself, as well as any related formulations or methods of use. If BR112014016788 is still in force and its claims are broad, it would prevent generic entry. Generic entry typically occurs after the expiry of all relevant and valid patents.
-
How can a competitor determine if their product infringes on this patent?
A competitor must conduct a detailed freedom-to-operate (FTO) analysis. This involves comparing the structure of their product and its intended use against the specific claims of the granted patent (if any) or the published claims of the application. It requires expert legal and technical interpretation of patent claims and comparison with the competitor's compound and its manufacturing process and therapeutic indication.
Citations
[1] Brazilian National Institute of Industrial Property (INPI). (n.d.). Patent Database Search. Retrieved from https://www.inpi.gov.br/ (Note: Specific search query for BR112014016788 would be required to retrieve direct official records)
